



Complement - a therapeutic target for stroke and ALS

Professor Marcela Pekna, MD, PhD

Director of the Laboratory of Regenerative Neuroimmunology
Dept. of Clinical Neuroscience, Sahlgrenska Academy at the University of
Gothenburg, Sweden

August 15, 2022, 13.30-14.30



At Milan Hasek Auditorium, Institute of Molecular Genetics of the Czech
Academy of Sciences, Vídeňská 1083, Praha 4

SELECTED PUBLICATIONS: *EMBO J* 25:1364, 2006; *Stem Cells* 27:2824, 2009; *Exp Neurol* 237:8, 2012; *Physiol Rev* 94:1077, 2014; *Exp Neurol* 253:154, 2012; ; *Acta Neuropathol* 131: 323, 2016; *Cereb Cortex* 27:3360, 2017; *Brain* 104:353, 2017; , *Exp Neurol* 290:74, 2017, *Front Immunol* 12: 768198, 2021; *Cells* 10:1812, 2021; *Neurochem Res* 46:2626, 2021; *Prog Neurobiol* 229:102199, 2022.

CITED > 11 000 times, h-index 46 (Google Scholar)

The complement system is a part of the innate immune system that protects the host against pathogens. Over the years, Marcela and others have identified novel functions of the complement system in neural plasticity, regeneration and responses of the brain in neurological diseases. The lecture will highlight recent findings from the Pekna laboratory that point to the complement C3a receptor as an attractive target for therapies aiming at improving recovery after ischemic stroke and slowing down the progression of amyotrophic lateral sclerosis.